CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, today announced that it will present a corporate update at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014, at 10:00 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. The presentation will be delivered by Brian Pereira, M.D., President and CEO of Visterra, who will provide an update on the company’s therapeutic pipeline of novel antibodies for infectious diseases.
Visterra also announced today that the company has launched an update to its website, www.visterrainc.com, to reflect the latest information on its drug candidates and programs and the capabilities of its proprietary Hierotope™ Platform, which is powered by Atomic Interactive Network (AIN) analysis.
Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design effective therapeutics. The company’s technology is powered by computational tools and techniques, called Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company is currently focused on therapeutics for infectious diseases and its lead antibody product candidate, VIS410, is a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. Visterra was founded based on scientific work developed in the laboratory of Dr. Ram Sasisekharan and licensed from MIT. The company is backed by Polaris Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation, Omega Funds and Alexandria Venture Investments. For more information please visit www.visterrainc.com.